When Stanford investigators discovered CD47's ability to disguise cancer cells and help them avoid detection, it transformed our understanding of the innate immune system and opened new avenues to create cancer-fighting therapies. How did this revelation move from basic-science studies to a lifesaving antibody therapeutic in late-stage clinical trials today? Ravi Majeti will chronicle this groundbreaking therapy's journey from the lab into the clinic and expound on the promise of Stanford's new Innovative Medicines Accelerator to bring future scientific discoveries to patients more quickly.